Barbaresi William J, Katusic Slavica K, Colligan Robert C, Pankratz V Shane, Weaver Amy L, Weber Kevin J, Mrazek David A, Jacobsen Steven J
Division of Developmental and Behavioral Pediatrics, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Arch Pediatr Adolesc Med. 2002 Mar;156(3):217-24. doi: 10.1001/archpedi.156.3.217.
The frequency of occurrence of attention-deficit/hyperactivity disorder (AD/HD) is in dispute. This uncertainty has contributed to the concern that too many children in the United States are being treated with stimulant medication.
To determine the cumulative incidence of AD/HD in a population-based birth cohort and to estimate the prevalence of pharmacologic treatment for children who fulfill research criteria for AD/HD.
Population-based birth cohort study.
All children born between 1976 and 1982 in Rochester, Minn, who remained in the community after age 5 years (N = 5718).
Medical and school records were reviewed for clinical diagnoses of AD/HD and supporting documentation (symptoms consistent with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and positive results for AD/HD-related questionnaires). Research-identified cases were defined as: (1) "definite" AD/HD (clinical diagnosis and at least one type of supporting documentation); (2) "probable" AD/HD (clinical diagnosis but no supporting documentation or no clinical diagnosis but both types of supporting documentation); (3) "questionable" AD/HD (no clinical diagnosis, but at least one type of supporting documentation); and (4) "not AD/HD" (all other subjects). Information about pharmacologic treatment for AD/HD was abstracted for all subjects.
The highest estimate of the cumulative incidence at age 19 years (with 95% confidence interval) of AD/HD (definite plus probable plus questionable AD/HD) was 16.0% (14.7-17.3). The lowest estimate (definite AD/HD only) was 7.4% (6.5-8.4). Prevalence of treatment with stimulant medication was 86.5% for definite AD/HD, 40.0% for probable AD/HD, 6.6% for questionable AD/HD, and 0.2% for not AD/HD.
These results provide insight into the apparent discrepancies in estimates of the occurrence of AD/HD, with less stringent criteria resulting in higher cumulative incidence. Children who met the most stringent criteria for AD/HD were most likely to receive pharmacologic treatment.
注意力缺陷多动障碍(AD/HD)的发病率存在争议。这种不确定性引发了人们对美国有过多儿童接受兴奋剂药物治疗的担忧。
确定以人群为基础的出生队列中AD/HD的累积发病率,并估计符合AD/HD研究标准的儿童接受药物治疗的患病率。
以人群为基础的出生队列研究。
1976年至1982年在明尼苏达州罗切斯特市出生、5岁后仍居住在该社区的所有儿童(N = 5718)。
查阅医疗和学校记录,以获取AD/HD的临床诊断及支持性文件(符合《精神障碍诊断与统计手册》第四版标准的症状以及AD/HD相关问卷的阳性结果)。经研究确定的病例定义为:(1)“确诊”AD/HD(临床诊断且至少有一种支持性文件);(2)“可能”AD/HD(临床诊断但无支持性文件,或无临床诊断但有两种支持性文件);(3)“可疑”AD/HD(无临床诊断,但至少有一种支持性文件);(4)“非AD/HD”(所有其他研究对象)。提取了所有研究对象关于AD/HD药物治疗的信息。
19岁时AD/HD(确诊加可能加可疑AD/HD)的累积发病率最高估计值(95%置信区间)为16.0%(14.7 - 17.3)。最低估计值(仅确诊AD/HD)为7.4%(6.5 - 8.4)。确诊AD/HD的儿童使用兴奋剂药物治疗的患病率为86.5%,可能AD/HD为40.0%,可疑AD/HD为6.6%,非AD/HD为0.2%。
这些结果有助于理解AD/HD发病率估计中明显的差异,标准越宽松,累积发病率越高。符合AD/HD最严格标准的儿童最有可能接受药物治疗。